NCT03601702Recruiting
EmboTrap ® II Revascularization Device (Neuravi) in Acute Ischemic Stroke
Multicentric Observational Prospective Study on the Use of the EmboTrap ® II Revascularization Device (Neuravi) in Acute Ischemic Stroke
Source: ClinicalTrials.gov · Last updated 16 Apr 2026
Brief summary (registry, in English)
The primary aim of Registrap study is to assess the safety and effectiveness of the EmboTrap®II Clot Retriever device (Neuravi) in patients with acute ischemic stroke from large vessel occlusion.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 11 May 2018
- Start date
- Jan 2022
- Primary completion date
- Dec 2025
- Lead sponsor
- Niguarda Hospital
- Diseases
- Stroke
- NCT number
- NCT03601702
What you commit to
- Study type: Observational
- Planned participants: 100
- From Jan 2022 to the primary completion date, Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Informed consent not given
- Extracranial or tandem occlusion
Who the study is looking for
- Signed Informed Consent Form
- Large Vessel Occlusion on CTA or MRA in the Anterior or Posterior Proximal Cerebral Vasculature up to A1, M1, Dominant M2, P1
- ASPECTS ≥ 6
- Mismatch or good collaterals showed at MR or multiphasic CTA or pCT
- Groin Puncture performed within 12 hours from symptom onset
- Use of EmboTrap® II Revascularization Device (Neuravi) as the first or second line treatment
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| ASST GOM Niguarda Coordinator of this site? Confirm its status | Milan | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.